Covetrus, Inc. CVET
We take great care to ensure that the data presented and summarized in this overview for COVETRUS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CVET
View all-
Sarissa Consulting LLC Santa Monica, CA31.7KShares$00.68% of portfolio
-
S. Muoio & Co. LLC New York, NY30.3KShares$00.84% of portfolio
-
Eaton Vance Management Boston, MA9.79KShares$00.0% of portfolio
-
Brewin Dolphin LTD London, X0592Shares$00.0% of portfolio
-
Wipfli Financial Advisors Llc,289Shares$00.0% of portfolio
-
American Portfolios Advisors Holbrook, NY240Shares$00.0% of portfolio
-
Fieldpoint Private Securities, LLC20Shares$00.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$00.0% of portfolio
Latest Institutional Activity in CVET
Top Purchases
Top Sells
About CVET
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.
Insider Transactions at CVET
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 13
2022
|
Sandra L Helton Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
38,095
-100.0%
|
-
|
Oct 13
2022
|
Philip A Laskawy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,064
-100.0%
|
-
|
Oct 13
2022
|
Matthew J. Foulston Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
95,079
-100.0%
|
-
|
Oct 13
2022
|
Deborah G Ellinger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,459
-100.0%
|
-
|
Oct 13
2022
|
Mark Jeffrey Manoff Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
26,595
-100.0%
|
-
|
Oct 13
2022
|
Benjamin Wolin President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
198,711
-100.0%
|
-
|
Oct 13
2022
|
Rebecca Ann Kidd Head of Global Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,028
-100.0%
|
-
|
Oct 13
2022
|
Matthew Malenfant Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
84,304
-100.0%
|
-
|
Oct 13
2022
|
Georgina Wraight Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
95,406
-100.0%
|
-
|
Oct 13
2022
|
Sandra E Peterson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,664
-100.0%
|
-
|
Oct 13
2022
|
Paul R. Fonteyne Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,275
-100.0%
|
-
|
Oct 13
2022
|
Ravi Sachdev Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
38,095
-100.0%
|
-
|
Oct 13
2022
|
Steven Paladino Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
74,844
-100.0%
|
-
|
Oct 13
2022
|
Edward Mc Namara Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
31,807
-100.0%
|
-
|
Oct 13
2022
|
Cd&R Investment Associates Ix, Ltd. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
33,670,541
-100.0%
|
-
|
Oct 01
2022
|
Rebecca Ann Kidd Head of Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
356
-1.75%
|
$7,120
$20.88 P/Share
|
Oct 01
2022
|
Rebecca Ann Kidd Head of Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
1,232
+5.7%
|
-
|
Sep 01
2022
|
Matthew J. Foulston Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,024
-1.07%
|
$20,480
$20.82 P/Share
|
Sep 01
2022
|
Matthew J. Foulston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,601
+2.64%
|
-
|
Sep 01
2022
|
Georgina Wraight Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,891
-8.52%
|
$177,820
$20.82 P/Share
|